Legacy UK Holdings has made an indicative offer of 62p/share for staffing firm Empresaria (LON: EMR), which follows two major shareholders encouraging the company to seek potential offers. The Planmatics consortium is not going ahead with the cash and loan notes offer of 60p/share, which it blames on a lack of due diligence materials. The share price jumped 76% to 44p.
Nativo Resources (LON: NTVO) has gained approval from the noteholders for the proposed restructuring. The notes will not be convertible until January 2032 unless the market capitalisation exceeds £35m. This means that the company is no longer in technical default. The share price recovered 45.5% to 0.4p.
Dr Graham Cooley has increased his stake in security technology provider Thruvision (LON: THRU) from 3.17% to 6.8% and Nicholas Slater has a 3.23% shareholding. This follows the recent capital raising. Allenby has been appointed as nominated adviser and broker. The share price improved 22.8% to 1.75p.
Diagnostic tests developer Abingdon Health (LON: ABDX) has won a new contract worth $2.5m. It is for a companion diagnostic test and covers feasibility to scale-up and manufacturing. The share price increased 8% to 6.75p.
Water and environmental testing company Metir (LON: MET) generated revenues of £931,000 in the six months to June 2025, compared with an adjusted £112,000. That includes £386,000 from a project in Qatar. Cash is £586,000. This provides the ability to invest in expanding the business. There will be second half revenues from the Sulphate Reducing Bacteria kits. The share price rose 6.9% to 0.775p.
Wine retailer Virgin Wines (LON: VINO) says full year revenues were flat at £59m, although this was slightly lower than expected. The commercial division sales were 24% higher, indicating that the new strategy is beginning to work. Consumer customer churn is reducing. Net cash was better than expected at £9.3m. The share price is 5.98% higher at 62p.
FALLERS
Digital mental health products developer Cambridge Cognition (LON: COG) has experienced delays in signing contracts and them generating revenues. Interim revenues fell 23% to £4.3m and full year guidance has been cut from £12.5m to £9.5m-£10m. This means that the full year loss would increase from £700,000 to £900,000. The share price slumped 23.1% to 25p.
Atlantic Lithium (LON: ALL) is progressing discussions for the mining lease of the Ewoyaa lithium project in Ghana. Cost savings will be made to focus on this project. Cash was A$5.4m at the end of June 2025. The share price slipped 6.63% to 7.89p.
Allergy Therapeutics (LON: AGY) has published three papers in the journal Allergy that improve the evidence for its Grass MATA MPL allergen immunotherapy. In one study the treatment was shown to be effective and well-tolerated. The share price declined 6.25% to 7.875p.
Wine maker Chapel Down (LON: CDGP) increased net sales revenues by 11% to £7.9m in the six months to June 2025. There was strong off-trade growth. Net debt increased to £11.3m. This is due to new plantings that will become productive over the next two years and an increase in inventory following the 2024 harvest. The level of the 2025 harvest should be known by October. Former ICAP boss and major shareholder in Chapel Down Michael Spencer will take over as chair in September. The share price fell 3.37% to 43p.
Ex-dividends
CML Microsystems (LON: CML) is paying a final dividend of 6p/share and the share price is unchanged at 308p.
James Latham (LON: LTHM) is paying a final dividend of 27.3p/share and the share price decreased 15p to 1165p.
Volex (LON: VLX) is paying a final dividend of 3p/share and the share price fell 6.25p to 373.75p.